Inquis Medical Secures Funding for Advancements in Thrombectomy
Inquis Medical, an innovative company in the realm of medical technologies, has announced a significant achievement in its funding endeavors. The company has successfully completed a $40 million Series B financing round, aimed at propelling the development of its groundbreaking Aventus Thrombectomy System. This funding round attracted considerable attention from both new and existing investors, signaling strong market confidence in Inquis Medical's vision and innovative technologies.
Investor Confidence in Inquis Medical
The recent financing was led by Marshall Wace, a well-respected investment firm noted for supporting promising ventures. In addition to Marshall Wace, the financing saw robust participation from existing investors like ShangBay Capital, Yu Star, and EnPointe Ventures. The oversubscription of this funding round illustrates the investor community's trust in Inquis Medical and its future advancements in medical technology.
Innovative Technology at the Core
At the heart of Inquis Medical's offerings lies the Aventus Precision Thrombectomy System™, which is at the forefront of the company’s mission to revolutionize thrombectomy procedures. This advanced system is equipped with proprietary tissue-sensing technology, delivering real-time insights into tissue composition. This ability significantly enhances the precision and control during medical procedures, heralding a new era in treatment for venous thromboembolic diseases.
Regulatory Approvals and Clinical Progress
Earlier this year, Inquis Medical achieved a remarkable milestone by receiving FDA 510(k) clearance for the Aventus Thrombectomy System™, as well as for its associated blood return system for peripheral indications. The company is actively nearing the end of patient enrollment in a pivotal FDA Investigational Device Exemption (IDE) clinical study focused on patients suffering from pulmonary embolism (PE).
Leadership Insights on the Investment
Vahid Saadat, the Co-CEO and Co-Founder, expressed genuine excitement over the successful funding, highlighting it as strong validation for Inquis Medical’s innovative mission. Mojgan Saadat, also Co-CEO and Co-Founder, emphasized that the backing from Marshall Wace and other investors showcases a strong belief in the capabilities of their technology and the team facilitating its growth.
Future Directions and Impact on Healthcare
The newly secured capital is a significant milestone in Inquis Medical's path to enhancing patient care through technology. The funding will not only facilitate the completion of the pivotal IDE trial but will also prepare the company for the commercial launch of the Aventus Thrombectomy System slated for 2025. Furthermore, Inquis Medical aims to further its cutting-edge tissue-sensing platform to improve procedural efficiencies.
Addressing a Critical Healthcare Need
The implications of Inquis Medical's innovations are profound, particularly in light of the staggering statistics surrounding venous thromboembolism (VTE) in the United States, where approximately 900,000 individuals are impacted annually. Given that over half of deep vein thrombosis cases can result in pulmonary embolism, which ranks as the third leading cause of cardiovascular deaths, the demand for effective solutions has never been clearer. Current procedures often encounter significant drawbacks, including blood loss and inefficiency, making Inquis Medical's advancements both timely and necessary.
Gratitude for Investor Support
The extensive support from various investors underscores the medical community's recognition of Inquis Medical's pioneering efforts. The company has expressed its heartfelt gratitude towards Marshall Wace and all stakeholders for their commitment, which will empower Inquis Medical to continue improving patient outcomes through advanced medical technologies.
About Inquis Medical
Inquis Medical is a clinical-stage medical device company dedicated to revolutionizing peripheral vascular treatments. With a focus on next-generation thrombectomy technologies, the company aims to provide physicians with enhanced control, precision, and reduced blood loss during procedures. Founded in 2020, Inquis Medical is backed by a seasoned leadership team boasting over 30 years of collective experience in developing and launching innovative medical devices to meet significant clinical needs.
Frequently Asked Questions
What does the Series B funding enable Inquis Medical to achieve?
The Series B funding allows Inquis Medical to complete its pivotal clinical trials and prepare for the commercial launch of the Aventus Thrombectomy System.
Who led the Series B financing for Inquis Medical?
The Series B financing was led by Marshall Wace, alongside strong participation from existing investors.
What is the Aventus Thrombectomy System?
The Aventus Thrombectomy System is an advanced medical device that utilizes proprietary tissue-sensing technology, enhancing precision during procedures.
How does Inquis Medical address VTE?
Inquis Medical targets venous thromboembolism by developing innovative solutions that improve procedural efficiency and minimize complications.
When will the Aventus Thrombectomy System be launched?
The planned commercial launch of the Aventus Thrombectomy System is set for 2025.
